When was CoTherix founded?

CoTherix was founded in 2000 and raised its 1st funding round 3 years after it was founded.

Where is CoTherix located?

CoTherix is headquartered in San Francisco, United States.

Is CoTherix a funded company?

CoTherix is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Oct 14, 2003.

When was the latest funding round of CoTherix?

CoTherix's latest funding was a $***** Series C round on Oct 14, 2003, with participation from 7 investors.

Where does CoTherix rank among its competitors?

CoTherix ranks 8th amongst 23 active competitors, of which 4 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Tenax Therapeutics, which secured $25M in Mar, 2025.

Who are the top competitors of CoTherix?

CoTherix's top competitors include Liquidia, Actelion and Gossamer Bio. Among them, Tenax Therapeutics secured the most recent funding round in March, 2025.

CoTherix - 2026 Company Profile, Team, Funding & Competitors

Q: Is CoTherix an acquired company?

CoTherix got acquired by Actelion on Nov 20, 2006.

Company Details

CoTherix (formerly known as Exhale Therapeutics) was focused on licensing and developing therapeutics for the treatment of cardiopulmonary and other chronic diseases. Its products include Ventavis (iloprost), an approved inhaled therapy for the treatment of pulmonary arterial hypertension. As of Jan 2007, the company was acquired by Actellion.

Key Metrics

Founded Year

2000

Location

San Francisco, United States

Stage

Acquired

Total Funding

$55M in 1 round

Latest Funding Round

Series C, Oct 14, 2003, $*****

Investors

Frazier Life Sciences & 8 more

Ranked

8^th among 23 active competitors

Similar Companies

Liquidia & 24 more

Exit Details

Acquired by Actelion (Nov 20, 2006)

View CoTherix's full profile

CoTherix got acquired by Actelion on Nov 20, 2006 at an acquisition amount of $*****.

Click here to take a look at CoTherix's acquisition in detail

CoTherix has raised a total funding of $55M over 1 round. Its latest funding round was a Series C round on Oct 14, 2003 for $*****. 7 investors participated in its latest round. CoTherix has 9 institutional investors.

Here is the list of recent funding rounds of CoTherix:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 14, 2003	2860478	Series C	2407038	5839975	7859246	8859250

Access funding benchmarks and valuations. Sign up today!

View details of CoTherix's funding rounds and investors

The founders of CoTherix are Donald Santel and Fred Volinsky.

Here are the details of CoTherix's key team members:

Donald Santel: Former Founder & CEO of CoTherix.
Fred Volinsky: Founder of CoTherix.

View details of CoTherix's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CoTherix include Liquidia, Actelion and Gossamer Bio. Here is the list of Top 10 competitors of CoTherix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	68/100
2nd	Actelion 1997, Allschwil (Switzerland), Acquired	Discovery, development, and commercialization of innovative treatments for orphan diseases	$46M	Atlas Venture, NeoMed & 11 others	63/100
3rd	Gossamer Bio 2017, San Diego (United States), Public	Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer	$330M	Hillhouse, Omega Funds & 15 others	57/100
4th	Tenax Therapeutics 1967, Morrisville (United States), Public	Developer of therapeutics to address cardiovascular and pulmonary diseases	-	RTW Investments, Westwicke & 1 others	52/100
5th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	51/100
6th	Vivus 1991, Mountain View (United States), Public	Developer of therapeutic solutions for obesity and sexual health	-	Colt Ventures, Athyrium Capital Management ... & 9 others	47/100
7th	Aerovate Therapeutics 2018, Boston (United States), Public	Developer of therapeutic solutions for pulmonary arterial hypertension	$75.8M	Sofinnova Investments, Atlas Venture & 1 others	42/100
8th	CoTherix 2000, San Francisco (United States), Acquired	Inhaled therapeutics for the treatment of cardiopulmonary diseases.	$55M	Frazier Life Sciences, Sofinnova Partners ... & 7 others	42/100
9th	tiakis BIOTECH 2000, Kiel (Germany), Series A	Developer of anti-inflammatory and tissue-protective drugs	-	Elevat3 Capital	39/100
10th	Apaxen 2018, Charleroi (Belgium), Series A	Developer of small molecules for treating pulmonary diseases	$3.64M	Theodorus, India Innovation Fund & 1 others	32/100